In a nutshell
This study examined whether 6 or 8 cycles of R-CHOP-21 (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy led to better survival outcomes in patients with newly diagnosed diffuse large B-cell lymphoma. This study concluded that outcomes following 6 or 8 cycles of R-CHOP-21 are similar for these patients.
R-CHOP-21 is the current standard treatment for adults with diffuse large-B cell lymphoma. This regimen is administered over 21 days (3 weeks). Previous research has typically involved 8 cycles of chemotherapy. However, 6 cycles are more commonly used in clinical practice. Whether 8 cycles leads to better survival outcomes compared to 6 cycles in patients with diffuse large B-cell lymphoma is unclear.
Methods & findings
This study compared the impact of 8 versus 6 cycles of R-CHOP on survival outcomes in adults with diffuse large B-cell lymphoma. This study involved 1170 patients. 87% of patients received six cycles and 13% received eight cycles of treatment. The average follow-up period was 5 years.
Eight cycles of treatment were not associated with a significantly improved overall survival compared to six cycles. Overall, the probability of survival after 5 years was similar for patients treated with six cycles (74%) or eight cycles (72%).
To adjust for differences in the patient population, 157 patients from each group were also compared. The probability of survival after 5 years remained similar for patients treated with six cycles (76%) or eight cycles (72%).
No difference in survival outcomes were observed based on age or disease risk status (low versus high-risk).
The bottom line
This study concluded that 6 or 8 cycles of R-CHOP-21 are similarly effective for patients with newly diagnosed diffuse large-B cell lymphoma.
The fine print
This study was retrospective, meaning it looked back in time to analyze data. Also, patients who received 8 cycles of R-CHOP had slightly poorer disease status than patients who received 6 cycles.
Published By :
Annals of oncology : official journal of the European Society for Medical Oncology
May 22, 2018
If you sign up for Medivizor, you'll receive PERSONALIZED updates that are JUST FOR YOU. Want to give it a try?